N@N

LONDON--([ BUSINESS WIRE ])--Lightlake Therapeutics Inc. (OTCBB: LLTP) (the aCompanya or aLightlakea), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it has launched its new corporate website, [ http://lightlaketherapeutics.com ], and will be conducting a conference call followed by a Q & A session on Tuesday, November 29, 2011 at 5:00 PM EST to update shareholders and other interested parties on the Companyas current endeavors.

Dr. Roger Crystal, Chief Executive Officer of Lightlake, aWith all the recent developments associated with Lightlake, we wanted a more up-to-date website that lets visitors readily read about our progress, particularly about the ongoing Phase II trials of our opioid antagonist-based nasal spray treatment for Binge Eating Disorder as well as the upcoming Phase II trials of our opioid antagonist-based nasal spray treatment for Bulimia Nervosa. We are very pleased with the new, more comprehensive lightlaketherapeutics.com and we hope those interested in our Company visit and enjoy it as well.a

Additionally, Lightlakeas latest corporate website offers visitors in-depth looks at the Companyas partnerships with institutions such as Lloyds Pharmacy, Celesio AG and Kingas College London, as well as Lightlakeas product pipeline including its research and development efforts regarding treatments for opioid painkillers,methadone, cocaine and amphetamine addictions.

The Company is also announcing the launch of a proof-of-concept research program related to its opioid antagonist patents for the treatment of cocaine, amphetamine and ecstasy abuse and addiction.

Members of Lightlakeas management team and board of directors intend to discuss these pursuits and its partnerships in detail with investors in its forthcoming conference call.

To join the conference call, use the dial-in information below. When prompted, ask for the "Lightlake Therapeutics Call" and/or be prepared to provide the conference ID.

Dial in at least 10 minutes before the call to ensure timely participation. A playback will be available until11:59 PMDecember 13, 2011. To listen, please call 1-877-660-6853 withinthe United Statesor1-201-612-7415 if calling internationally.

About Lightlake Therapeutics, Inc.

Lightlake Therapeutics Inc. is a developing biopharmaceutical company aiming to build a platform of biopharmaceutical solutions to common addictions and related disorders. Currently, the Company is focused on providing a safe, effective and simple treatment for patients who are obese or overweight as a result of Binge Eating Disorder in addition to those patients suffering from Bulimia Nervosa. Lightlake recently acquired patents that will allow it to widen its product pipeline to address patients with addictions to opioid painkillers,methadone, cocaine and amphetamine. The Company anticipates launching a development program for each of these purposes in the future.

Safe Harbor

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.